ReviewMedComm2026
Radiotherapy-Induced Side Effects: Epidemiology, Pathogenesis, Prevention and Treatments.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The widespread application of radiotherapy for malignancies underscores the urgent clinical challenge of radiation-induced multiorgan injury, which severely impacts patient prognosis and quality of life. The heart, skin, lungs, intestines, hematopoietic system, oral, kidney, and brain are the most frequently affected sites, each following distinct and complex injury trajectories. Despite growing research into these organ-specific injuries, a substantial translational gap remains between mechanistic insights and effective therapeutic interventions. This review systematically delineates the unique epidemiological and pathological processes in these eight critical systems. It then critically evaluates current clinical management alongside emerging therapeutic strategies, including advanced radioprotectors, mitigators, antifibrotic agents, and innovative stem cell therapies. Central to our analysis is the synthesis of these findings into a comprehensive view of the complex interactive networks and functional imbalances driven by aberrant intercellular communication within damaged tissues. By offering a systematic analysis of mechanism-network-targeted therapeutics, this review establishes a critical framework to guide the future development of more effective, integrated, and personalized patient care strategies in radiation oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.